Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma : a Retrospective Multicenter Nested Case-control Study (CHANCE 2407)
Sponsor: Changzhou No.2 People's Hospital
This observational or N/A phase trial investigates HCC - Hepatocellular Carcinoma and Liver Abscess and is currently actively recruiting participants. Changzhou No.2 People's Hospital leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
2 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changzhou No.2 People's Hospital
- First Hospital of China Medical University
- Huazhong University of Science and Technology
- Shengjing Hospital
- Tianjin Medical University General Hospital
- Zhongda Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.